Hysbysiad dyfarnu contract
Canlyniadau'r weithdrefn gaffael
Adran I:
Endid
contractio
I.1) Enw a chyfeiriad
Betsi Cadwaladr University Health Board
Headquarters, Ysbyty Gwynedd, Penrhosgarnedd
Bangor
LL57 2PW
UK
Person cyswllt: Vicky Allum
Ffôn: +44 2921501263
E-bost: vicky.allum@wales.nhs.uk
NUTS: UKL
Cyfeiriad(au) rhyngrwyd
Prif gyfeiriad: https://bcuhb.nhs.wales/
Cyfeiriad proffil y prynwr: https://www.sell2wales.gov.wales/search/Search_AuthProfile.aspx?ID=AA88547
I.2) Caffael ar y cyd
Caiff y contract ei ddyfarnu gan gorff prynu canolog
I.4) Y math o awdurdod contractio
Corff a lywodraethir gan gyfraith gyhoeddus
I.5) Prif weithgaredd
Iechyd
Adran II: Gwrthrych
II.1) Cwmpas y caffaeliad
II.1.1) Teitl
Edoxaban Review Service W91017
Cyfeirnod: BCU-MSP02-Edoxaban-W91017
II.1.2) Prif god CPV
85121100
II.1.3) Y math o gontract
Gwasanaethau
II.1.4) Disgrifiad byr
The service is to review those prescribed edoxaban in primary care with a view to changing them to a more cost effective alternative.
II.1.6) Gwybodaeth am lotiau
Mae’r contract hwn wedi’i rannu’n lotiau:
Na
II.1.7) Cyfanswm gwerth y caffaeliad
Gwerth heb gynnwys TAW: 6 180.00 GBP
II.2) Disgrifiad
II.2.2) Cod(au) CPV ychwanegol
85121100
II.2.3) Man cyflawni
Cod NUTS:
UKL
UKL23
II.2.4) Disgrifiad o’r caffaeliad
Edoxaban Review Service is a service that requires a clinical review of all patients prescribed edoxaban for atrial fibrillation registered with GPs in BCUHB to assess if they are suitable for a more cost effective alternative and then change those that are.
Part 1 - Edoxaban Patient Review
Clinical review of the records of patients prescribed edoxaban.
Anyone not deemed suitable for the switch must be evidenced in the records, consider using the phrase
Edoxaban switch not clinically appropriate (no code) or,
Edoxaban contraindicated (SNOMED CT:2949391000000118) or,
Adverse reaction to edoxaban (SNOMED CT:1957181000006103).
Those deemed suitable for a switch proceed to a consultation with the patient or their representative. Consultations to switch edoxaban to generic apixaban or generic rivaroxaban can be done via telephone, virtually or face-to-face.
This must be documented in the notes, consider using the phrase
Edoxaban switch clinically appropriate (no code) or,
Edoxaban declined (SNOMED CT:1443911000000106)
Part 2 - Edoxaban Patient Review that results in a switch to generic apixaban or generic rivaroxaban
If clinically appropriate and the patient agrees to the switch to either generic rivaroxaban or generic apixaban; prescribe as indicated.
This is a new service and will run from 1st August 2026 until 31st January 2027.
This is a Provider Selection Regime Wales (PSR Wales) intention to award notice. The awarding of this contract is subject to the Health Services (Provider Selection Regime) (Wales) Regulations 2025. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015/Procurement Act 2023 do not apply to this award.
II.2.5) Meini prawf dyfarnu
Maes prawf ansawdd: most suitable provider process with regard to the key criteria
/ Pwysoliad: 100
Maen prawf cost: most suitable provider process with regard to the key criteria
/ Pwysoliad: pass
II.2.11) Gwybodaeth am opsiynau
Opsiynau:
Na
II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd
Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd:
Na
Section IV: Gweithdrefn
IV.1) Disgrifiad
IV.1.1) Y math o weithdrefn
Dyfarnu contract heb gyhoeddi galwad am gystadleuaeth yng Nghyfnodolyn Swyddogol yr Undeb Ewropeaidd ymlaen llaw
Cyfiawnhau'r weithdrefn ddyfarnu a ddewiswyd:
Mae’r caffaeliad y tu allan i gwmpas cymhwysiad y gyfarwyddeb
Esboniad
‘This is a Provider Selection Regime Wales (PSR Wales) intention to award notice. The awarding of this contract is subject to the Health Services (Provider Selection Regime) (Wales) Regulations 2025. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015/Procurement Act 2023 do not apply to this award. The publication of this notice marks the start of the standstill period. Representations by providers must be made to decision makers by 11.59pm 6th August 2026. This contract has not yet formally been awarded; this notice serves as an intention to award under the PSR Wales'.
IV.1.8) Gwybodaeth am Gytundeb Caffael y Llywodraeth (GPA)
The procurement is covered by the Government Procurement Agreement:
Ydy
IV.2) Gwybodaeth weinyddol
IV.2.1) Cyhoeddiad blaenorol mewn perthynas â’r weithdrefn hon
Rhif yr hysbysiad yn OJ S:
2026/S 000-064486
Section V: Dyfarnu contract
Rhif Contract: BCU-MSP02-Edoxaban-W91017
Dyfernir contract/lot:
Ydy
V.2 Dyfarnu contract
V.2.1) Y dyddiad y daeth y contract i ben
20/07/2026
V.2.2) Gwybodaeth am dendrau
Nifer y tendrau a ddaeth i law: 1
Nifer y tendrau a ddaeth i law gan BBaChau: 1
Nifer y tendrau a dderbyniwyd gan dendrwyr o Aelod-wladwriaethau yr UE: 0
Nifer y tendrau a dderbyniwyd gan dendrwyr o Aelod-wladwriaethau nad ydynt yn aelodau o'r UE: 0
Nifer y tendrau a ddaeth i law drwy ddulliau electronig: 0
Dyfarnwyd y contract i gr?p o weithredwyr economaidd:
Na
V.2.3) Enw a chyfeiriad y contractwr
Pendre Surgery
Pendre Surgery, Clayton Road
Mold
CH7 1SS
UK
Ffôn: +44 1352744381
NUTS: UK
BBaCh yw’r contractwr:
Ydy
V.2.4) Gwybodaeth am werth y contract/lot (heb gynnwys VAT)
Cyfanswm gwerth y contract/lot: 6 180.00 GBP
V.2.5) Gwybodaeth am is-gontractio
Section VI: Gwybodaeth ategol
VI.3) Gwybodaeth ychwanegol
This is a Provider Selection Regime Wales (PSR Wales) intention to award notice. The awarding of this contract is subject to the Health Services (Provider Selection Regime) (Wales) Regulations 2025. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015/Procurement Act 2023 do not apply to this award. The publication of this notice marks the start of the standstill period. Representations by providers must be made to decision makers by 11.59pm 6th August 2026. This contract has not yet formally been awarded; this notice serves as an intention to award under the PSR Wales.
The decision makers were the Associate Director Primary Care, Medical Director Primary Care, Head of Pharmacy Primary Care, Primary Care Contracts Manager and Clinical Governance Managers. There are no noted conflict of interests.
As part of the review all basic and key criteria were included with a pass/ fail weighting for all criteria and an award being made when all criteria were met. The Health Board determined that, due to the low-risk and highly specified nature of the service, providers would be assessed against mandatory requirements aligned to the PSR key criteria. Providers demonstrating appropriate clinical governance arrangements, capacity to deliver the reviews within the service period, compliance with the DOAC LSS and acceptance of the service specification were awarded contracts. Providers failing to satisfy one or more mandatory requirements were not awarded. This provider met all criteria.
(WA Ref:168377)
VI.4) Gweithdrefnau adolygu
VI.4.1) Corff adolygu
High Court
Royal Courts of Justice, The Strand
London
WC2A 2LL
UK
Ffôn: +44 2079477501
VI.5) Dyddiad anfon yr hysbysiad hwn
27/07/2026